Valuation: StemCell Institute Inc.

Market Cap 7.54B 48.62M 42.12M 39.83M 36.06M 67.67M 4.66B 68.18M 475M 183M 2.37B 183M 179M P/E 2026
49.6x
P/E 2027 * 94.8x
Enterprise Value 7.54B 48.62M 42.12M 39.83M 36.06M 67.67M 4.66B 68.18M 475M 183M 2.37B 183M 179M EV / Sales 2026
2.74x
EV / Sales 2027 * 2.58x
Free-Float
22.67%
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week-0.27%
Current month-1.96%
1 month-2.34%
3 months+12.44%
6 months-8.76%
Current year-5.42%
1 week 739
Extreme 739
753
1 month 739
Extreme 739
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
976
3 years 627
Extreme 627
2,669
5 years 627
Extreme 627
3,290
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 01/06/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 53 01/09/2013
Director/Board Member 81 01/06/2015
Director/Board Member 66 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%-0.27%-20.55%-71.43% 48.62M
-1.11%-1.64%+28.63%+33.33% 121B
-0.39%+5.42%+5.12%+65.37% 91.76B
+0.15%+1.58%-3.14%+52.16% 29.51B
+3.86%+4.92%+36.80%+95.75% 27.27B
-0.43%-0.78%-4.24%-2.58% 21.46B
-1.38%+0.69%+39.68%+273.82% 21B
-0.30%-1.39%-7.00%+28.35% 15.65B
+0.56%+2.55%-5.42%-5.26% 12.17B
+0.83%+6.02%+45.78%+94.14% 12.17B
Average +0.15%+1.52%+11.57%+56.37% 35.19B
Weighted average by Cap. -0.26%+1.65%+16.95%+60.80%

Financials

2026 2027 *
Net sales 2.87B 18.5M 16.03M 15.15M 13.72M 25.75M 1.77B 25.94M 181M 69.58M 900M 69.5M 67.96M 2.92B 18.82M 16.31M 15.42M 13.96M 26.2M 1.81B 26.4M 184M 70.79M 916M 70.71M 69.14M
Net income 180M 1.16M 1.01M 950K 860K 1.61M 111M 1.63M 11.34M 4.36M 56.44M 4.36M 4.26M 80M 516K 447K 422K 382K 718K 49.47M 723K 5.04M 1.94M 25.08M 1.94M 1.89M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
16/09/26 ¥750.00 +0.13% 800
15/09/26 ¥749.00 +0.13% 4,000
14/09/26 ¥748.00 0.00% 2,700
11/09/26 ¥748.00 -0.27% 1,500
10/09/26 ¥750.00 -0.27% 1,200

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!